Andrew Cittadine Purchases 12,000 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) COO Andrew Cittadine purchased 12,000 shares of the stock in a transaction dated Thursday, June 13th. The shares were acquired at an average price of $0.91 per share, with a total value of $10,920.00. Following the completion of the acquisition, the chief operating officer now owns 129,624 shares in the company, valued at approximately $117,957.84. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Andrew Cittadine also recently made the following trade(s):

• On Monday, June 17th, Andrew Cittadine purchased 12,000 shares of Monopar Therapeutics stock. The shares were acquired at an average price of $0.90 per share, with a total value of $10,800.00.
• On Monday, June 3rd, Andrew Cittadine purchased 12,000 shares of Monopar Therapeutics stock. The shares were acquired at an average price of $0.76 per share, with a total value of $9,120.00.
• On Friday, May 31st, Andrew Cittadine bought 12,000 shares of Monopar Therapeutics stock. The shares were purchased at an average price of $0.64 per share, with a total value of $7,680.00.
• On Wednesday, May 29th, Andrew Cittadine bought 12,000 shares of Monopar Therapeutics stock. The shares were purchased at an average price of $0.64 per share, with a total value of $7,680.00.

Monopar Therapeutics Price Performance

MNPR stock opened at $0.83 on Wednesday. The firm has a market capitalization of $14.46 million, a P/E ratio of -1.59 and a beta of 1.15. The business’s 50-day moving average is $0.71 and its two-hundred day moving average is $0.60. Monopar Therapeutics Inc. has a 1 year low of $0.27 and a 1 year high of $1.73.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. On average, analysts expect that Monopar Therapeutics Inc. will post -0.37 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on MNPR. Jonestrading upgraded Monopar Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a report on Thursday, April 11th. HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of Monopar Therapeutics in a report on Friday, May 10th.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.